Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer

Overview

Journal Front Pharmacol

Date 2022 Jun 23

PMID 35734411

Authors

Dehua Liao

Lun Yu

Dangang Shangguan

Yongchang Zhang

Bowen Xiao

Ni Liu

Nong Yang

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases. Fortunately, the development of molecular oncology provides a promising and effective therapeutic strategy for lung cancers, including specific gene mutations/translocations and immune checkpoints, with epidermal growth factor receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later as the targeted therapy and immune checkpoint inhibitors (ICIs) as immunotherapy. This review summarized the recent therapy advancements of TKIs and ICIs in NSCLC and focused on the clinical effect of combination or sequential treatment so as to provide the effective advice for the treatment of NSCLC.

Citing Articles

Comparison of Prognostic Values of Seven Immune Indexes in Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab: How Effective Can They Be Regarding Our Treatment Decisions?.

Ulas A, Temel B, Kos F Medicina (Kaunas). 2024; 60(11).

PMID: 39596977 PMC: 11596302. DOI: 10.3390/medicina60111792.

Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC).

Mohamedkhan S, Hindocha S, de Boisanger J, Millard T, Welsh L, Rich P Cancers (Basel). 2024; 16(6).

PMID: 38539550 PMC: 10969132. DOI: 10.3390/cancers16061218.

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer.

Hu Z, Wang N, Zhang Y, Zhang D, Sun S, Yu H Transl Lung Cancer Res. 2024; 13(2):345-354.

PMID: 38496687 PMC: 10938106. DOI: 10.21037/tlcr-24-29.

Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.

Chen Y, Gong L, Gu P, Hua Y, Sun Y, Ni S BMC Cancer. 2023; 23(1):944.

PMID: 37803437 PMC: 10557237. DOI: 10.1186/s12885-023-11366-4.

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.

Li Y, Mao T, Wang J, Zheng H, Hu Z, Cao P Cell Commun Signal. 2023; 21(1):71.

PMID: 37041601 PMC: 10088170. DOI: 10.1186/s12964-023-01082-8.

References

Oshima Y, Tanimoto T, Yuji K, Tojo A . EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(8):1112-1115. PMC: 5885195. DOI: 10.1001/jamaoncol.2017.4526. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Doebele R, Pilling A, Aisner D, Kutateladze T, Le A, Weickhardt A . Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18(5):1472-82. PMC: 3311875. DOI: 10.1158/1078-0432.CCR-11-2906. View

Fossella F, Pereira J, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E . Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003; 21(16):3016-24. DOI: 10.1200/JCO.2003.12.046. View

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J . Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016; 387(10030):1837-46. DOI: 10.1016/S0140-6736(16)00587-0. View

Hsu K, Huang Y, Tseng J, Chen K, Ku W, Su K . High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019; 127:37-43. DOI: 10.1016/j.lungcan.2018.11.021. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Paz-Ares L, Tan E, OByrne K, Zhang L, Hirsh V, Boyer M . Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol. 2017; 28(2):270-277. PMC: 5391700. DOI: 10.1093/annonc/mdw611. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

10.

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

11.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

12.

Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S . Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020; 15(10):1636-1646. DOI: 10.1016/j.jtho.2020.07.014. View

13.

Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H . Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res. 2012; 18(22):6219-26. DOI: 10.1158/1078-0432.CCR-12-0392. View

14.

Azzoli C, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J . American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(36):6251-66. PMC: 2793036. DOI: 10.1200/JCO.2009.23.5622. View

15.

Kotake M, Murakami H, Kenmotsu H, Naito T, Takahashi T . High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy. Ann Oncol. 2016; 28(3):669-670. DOI: 10.1093/annonc/mdw647. View

16.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

17.

Murray B, Zhai D, Deng W, Zhang X, Ung J, Nguyen V . TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. Mol Cancer Ther. 2021; 20(9):1499-1507. PMC: 9398166. DOI: 10.1158/1535-7163.MCT-21-0221. View

18.

Su S, Dong Z, Xie Z, Yan L, Li Y, Su J . Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. J Thorac Oncol. 2018; 13(11):1668-1675. DOI: 10.1016/j.jtho.2018.07.016. View

19.

Gainor J, Shaw A, Sequist L, Fu X, Azzoli C, Piotrowska Z . EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016; 22(18):4585-93. PMC: 5026567. DOI: 10.1158/1078-0432.CCR-15-3101. View

20.

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J . Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer. Clin Cancer Res. 2015; 21(17):4014-21. DOI: 10.1158/1078-0432.CCR-15-0016. View